Skip to main content

REVIEW article

Front. Public Health
Sec. Infectious Diseases: Epidemiology and Prevention
Volume 12 - 2024 | doi: 10.3389/fpubh.2024.1390951
This article is part of the Research Topic Reviews in Vaccination Programmes View all 11 articles

COVID-19 vaccinationa real challenge in pediatric population

Provisionally accepted
Alice Nicoleta Azoicai Alice Nicoleta Azoicai 1Ingrith Miron Ingrith Miron 1Ancuta Lupu Ancuta Lupu 1*Monica Mihaela Alexoae Monica Mihaela Alexoae 1IULIANA MAGDALENA STARCEA IULIANA MAGDALENA STARCEA 1Mirabela Alecsa Mirabela Alecsa 1Vasile Valeriu Lupu Vasile Valeriu Lupu 1*Ciprian Danielescu Ciprian Danielescu 1Alin Horatiu Nedelcu Alin Horatiu Nedelcu 1Delia Lidia Salaru Delia Lidia Salaru 1Felicia Dragan Felicia Dragan 2Ileana Ioniuc Ileana Ioniuc 1
  • 1 Grigore T. Popa University of Medicine and Pharmacy, Iași, Iasi, Romania
  • 2 Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Bihor, Romania

The final, formatted version of the article will be published soon.

    Vaccination is considered to be one of the most effective interventions for individual and collective protection of the population against the risks caused by exposure to various pathogens. The COVID-19 infection caused a severe acute respiratory syndrome that affected population of all ages, worldwide. Since that moment, several pharmaceutical companies had the opportunity and the industrial means to develop a vaccine in a very short period of time, releasing new, improved and combined vaccines for community immunization. This review aims to present a summary of the literature data regarding the efficiency and safety of COVID-19 vaccine in pediatric population (0 to 18 years), by analyzing the most recent published studies. Most of clinical trials that were reviewed in this article reported sustained immune response after COVID-19 vaccination in children of all age-groups, worldwide. The effectiveness and safety of immunization schedule in children and adolescents were also highlighted by most of the authors. Population-level effectiveness of this vaccination is still to be determined, as long as the beneficial response overcomes the potential risks. There is still the need to monitor the long-term side-effects, in order to have the opportunity to develop new, safer and more effective vaccines to reduce the impact of a new pandemic.

    Keywords: Vaccine, COVID-19, SARS-CoV-2, Efficiency, Safety, Children

    Received: 24 Feb 2024; Accepted: 24 Dec 2024.

    Copyright: © 2024 Azoicai, Miron, Lupu, Alexoae, STARCEA, Alecsa, Lupu, Danielescu, Nedelcu, Salaru, Dragan and Ioniuc. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Ancuta Lupu, Grigore T. Popa University of Medicine and Pharmacy, Iași, 700115, Iasi, Romania
    Vasile Valeriu Lupu, Grigore T. Popa University of Medicine and Pharmacy, Iași, 700115, Iasi, Romania

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.